Media Center

enGenes Biotech has created a portfolio of high-performance products to transform bioprocessing — from upstream fermentation to downstream purification. The portfolio includes a cost-effective endonuclease and a versatile range of affinity ligands, all produced using the proprietary enGenes-eXpress™, -eXtra™, and -eXcite™ platforms to deliver reliability, scalability, and efficiency. -eXrase™, ™ for smart DNA digestion, Real Cost Savings -eXrase™, is a next-generation recombi

Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) will return to the influential Swiss Biotech Day conference in Basel, at the heart of Switzerland’s thriving cluster of life science industries and research. The enGenes team in Basel, led by Head of Business Development, Dr. Karl Hübler, will take part in Swiss Biotech Day’s many networking activities, including one-on-one partnering meetings and its Global Village that hosts delegations f

Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech will be a scientific contributor to the third ECI Microbial Engineering Conference (ME III), sharing its latest advances towards continuous production of biotechnological products. Led by Mr. Florian Simon, the enGenes team at ME III will present the latest data from its participation in the ECOnti project that is developing an accelerated, low ecological footprint manufacturing platform for the continuou

Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech will be a prominent presence at the BioProcess Summit Europe in Barcelona, later this month. The enGenes team under the leadership of its CEO Dr. Juergen Mairhofer will make two contributions to the conference program, highlighting different aspects of its pioneering work towards continuous production of biotechnological products, as part of the European ECOnti Project. ECOnti explained On the final day o

This whitepaper introduces the enGenes-expand technology, the site-specific incorporation of non-canonical amino acids (NCAAs) by amber-stop codon suppression. This technology has vast applications in fields like protein engineering, drug discovery, and biotechnology, by enabling the synthesis of modified proteins with tailored properties, as well as the cost-effective incorporation of NCAAs into proteins for bioconjugation through click-chemistry. This approach, which overla

enGenes Biotech has developed -eXchange™ as an optimized solution for the cost-effective production of recombinant proteins and plasmid DNA that are free of antibiotic resistance genes. It can be used in conjunction with other enGenes technology platforms, such as -eXpress™ and enGenes-eXtra™ for enhanced production of very high-quality plasmid DNA (pDNA) and recombinant proteins, allowing for faster-track production of enzymes and antigen development, for instance. enGenes-e

The latest White Paper from advanced biotechnological solutions developer enGenes Biotech discusses solutions for improving the efficacy, safety and production yields of plasmid DNA. The technical article Advancing Plasmid DNA Manufacturing is authored by enGenes Biotech CEO and CSO Dr. Juergen Mairhofer. It introduces the enGenes -eXcess™ and enGenes -eXchange™ technologies as groundbreaking advances that improve production yields with up to 3 g/l of supercoiled plasmid DNA,

We're thrilled to announce that our CEO, Dr. Juergen Mairhofer, will be participating in the European Summit of Industrial Biotechnology...

Advanced biotechnological solutions developer enGenes Biotech has released a new White Paper discussing industrial applications for its...

Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech will bring insights on its latest technological advances in...